Generation Bio announces strategic reorganization

Generation Bio (GBIO) announced a strategic reorganization to prioritize investment in the development of its cell-targeted lipid nanoparticle delivery system for wholly-owned programs in extrahepatic cell types. Generation Bio intends to continue to develop ctLNP for immune cells as part of its collaboration with Moderna and to develop its immune-quiet DNA, or iqDNA, for its lead hemophilia A and other programs. The reorganization actions and financial impacts are as follows: Streamlining R&D to develop wholly-owned ctLNP programs for extrahepatic cell types; Continuing to develop immune cell programs with Moderna (MRNA); Continuing to develop the iqDNA platform for its lead hemophilia A and other programs; Extending cash runway into the second half of 2027; The company will reduce its total workforce by 40%, while preserving core R&D capacity. Several of Generation Bio’s leadership team members will also depart as part of the reorganization.